Project Grant R01CA308808
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $185,760.00 to The Regents of the University of California, San Francisco under the Cancer Research Manpower program (CFDA 93.398) on July 7, 2025. This Project Grant funds research aimed at enhancing treatment outcomes for metastatic castration-resistant prostate cancer (MCRPC) through the development of novel tumor-targeted combination therapy. The primary research deliverable involves creating a single...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $615,399 Project Grant to the University of California, Davis under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2025, through July 31, 2030. The award supports the development of a transformable nanoparticle (TNP) platform designed to deliver therapeutic peptides and proteins directly to tumor microenvironments on-demand. The TNP technology transforms from nanoparticles to nanofibrils...
- Federal Grant Award Summary The National Cancer Institute awarded a $410,933 Project Grant (CFDA 93.395 – Cancer Treatment Research) to the University of California, San Diego on March 18, 2026, with completion targeted for February 29, 2028. This exploratory research grant (R21 mechanism) supports the development of next-generation small interfering RNA (siRNA) therapeutics designed to enhance delivery of siRNA molecules into metastatic castration-resistant prostate cancer (MCRPC) tumor cells...
- Federal Project Grant Award Summary The University of California, Davis received a $149,394 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective August 1, 2025 through July 31, 2030. This award supports research in targeted radiotheranostics—the development and clinical translation of diagnostic and therapeutic radiopharmaceuticals that enable integrated imaging and treatment of cancer. The research encompasses the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $648,177 to the University of California, Davis under the Cancer Biology Research program (CFDA 93.396) on April 1, 2026, for a project extending through February 28, 2031. The award supports fundamental research into glycolytic metabolic heterogeneity at the single-cell level, addressing a critical gap in understanding how glucose disposal and lactate production vary across cellular populations. The research team...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a Project Grant of $679,290 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the period April 1, 2026 through March 31, 2031. The project focuses on translating novel hyperpolarized (HP) carbon-13 dual-agent magnetic resonance imaging (MRI) techniques to improve prostate cancer detection and biopsy guidance. The research aims to develop and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of California, Los Angeles a $404,972 Project Grant effective August 1, 2025, through July 31, 2027, under the Cancer Treatment Research program (CFDA 93.395). This award supports fundamental and applied research investigating mechanisms of radiopharmaceutical therapy (RPT) resistance in metastatic castration-resistant prostate cancer. The research will evaluate how the ectonucleotidase enzyme ENPP1...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $988,224 to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025 through August 31, 2029. This project grant supports clinical research activities focused on advancing treatment strategies for head and neck cancer patients with competing health risks, particularly older populations and medically underserved groups who are ineligible for...
- Federal Grant Award Summary The National Cancer Institute awarded a $409,141 Project Grant to the University of California, Davis, effective June 1, 2026, through May 31, 2028, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). The grant supports research and development of perfusion computed tomography (CT) imaging technology as an alternative diagnostic tool for liver radioembolization treatment planning. The project aims to validate contrast-enhanced perfusion CT as a...
The National Cancer Institute (NCI) awarded University of California, Davis a $551,328 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, with a completion date of March 31, 2031. This five-year research initiative focuses on dissecting the role of Carnitine Palmitoyltransferase 1C (CPT1C) in advanced prostate cancer, specifically neuroendocrine prostate cancer (NEPC), an aggressive subtype that emerges from castration-resistant prostate cancer following long-term androgen deprivation therapy. The project addresses a critical clinical need, as NEPC exhibits poor prognosis with low five-year survival rates and limited therapeutic options. The research deliverables encompass three integrated aims: (1) elucidating CPT1C's role in prostate cancer progression, neural lineage plasticity, and resistance to therapies such as enzalutamide; (2) investigating CPT1C protein regulation mechanisms and evaluating pharmacological modulation through in vitro and in vivo models; and (3) validating CPT1C as a therapeutic target using RNA bioengineering technologies and liposome-polyethylenimine nanocomplexes for targeted drug delivery. These research activities will be conducted at UC Davis's Sacramento, California campus and are expected to generate fundamental scientific knowledge and therapeutic insights applicable to treating advanced prostate cancer patients.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $551.3k | 3/20/26 |